- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2002.
-
- Dec.12.2002
- Ono Obtains an ISO14001 Certification for Its Fujiyama Plant(14 KB)
-
- Nov.01.2002
- Discontinuation of ONO-6818 Development for Chronic Obstructive Pulmonary Disease and Alpha 1 Antitrypsin Deficiency(8 KB)
-
- Sep.18.2002
- Announcement regarding the Results of Repurchese of Own Shares through ToSTNeT-2(13 KB)
-
- Sep.17.2002
- Notice regarding Repurchase of Own Shares through ToSTNeT-2(15 KB)
-
- Sep.09.2002
- Announcement of the Suspension of Overseas Clinical Study with Elaspol® 100 for Injection(59 KB)
-
- Sep.05.2002
- Announcement of the Launch of Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker(48 KB)
-
- Aug.26.2002
- Schering-Plough launched Leukotriene Antagonist Pranlukast in Mexico(45 KB)
-
- Jul.30.2002
- Ono Pharmaceutical Received Approval to Relinquish the Entrusted Portion of the Employee Pension Fund(44 KB)
-
- Jul.23.2002
- Announcement of Manufacturing Approval for Onoact® 50 for Injection, Japan's First Short-Acting Selective β1 Blocker(47 KB)
-
- Jun.13.2002
- Announcement of the Launch of Elaspol® 100 for Injection, the World's First Drug for Acute Lung Injury(44 KB)
-
- May.17.2002
- Notice regarding Repurchase of Ono Pharmaceutical's Own Shares(Under Article 210 of Japanese Commercial Code)(46 KB)
-
- May.17.2002
- Ono Pharmaceutical Improves Efficiency of Its Production System(43 KB)
-
- May.15.2002
- Announcement of Manufacturing Approval for Elaspol® 100 for Injection, the World's First Drug for Acute Lung Injury(46 KB)
-
- Jan.28.2002
- Notice regarding Purchase of Ono Pharmaceutical's Own Shares in the Market(48 KB)